골다공증 치료 약제와 턱뼈괴사증의 이해

키워드

참고문헌 (22)

1. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update", J Oral Maxillofac Surg, 72, pp.1938~ (2014)
2. Black DM, "Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group", J Clin Endocrinol Metab, 85, pp.4118~ (2000)
3. Reginster J, "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group", Osteoporos Int, 11, pp.83~ (2000)
4. Recker RR, "Oral ibandronate preserves trabecular microarchitecture:micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study", J Clin Densitom, 12, pp.71~ (2009)
5. Black DM, "The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)", J Bone Miner Res, 27, pp.243~ (2012)
6. Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~ (2003)
7. Henry DH, "Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma", J Clin Oncol, 29, pp.1125~ (2011)
8. Lipton A, "Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised, phase 3 trials", Eur J Cancer, 48, pp.3082~ (2012)
9. Sinningen K, "Skeletal and extraskeletal actions of denosumab", Endocrine, 42, pp.52~ (2012)
10. Aghaloo TL, "Osteonecrosis of the jaw in a patient on Denosumab", J Oral Maxillofac Surg, 68, pp.959~ (2010)
11. Papapoulos S, "Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension", J Bone Miner Res, 27, pp.694~ (2012)
12. Orwoll E, "A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density", J Clin Endocrinol Meatb, 97, pp.3161~ (2012)
13. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~ (2009)
14. Bone HG, "The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension", J Clin Endocrinol Metab, 98, pp.4483~ (2013)
15. Srivastava A, "Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis", Support Care Cancer (2020)
16. Cosman F, "Romosozumab Treatment in Postmenopausal Women with Osteoporosis", N Engl J Med, 375, pp.1532~ (2016)
17. Cosman F, "FRAME Study:The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab", J Bone Miner Res, 33, pp.1219~ (2018)
18. Khan AA, "Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus", J Bone Miner Res, 30, pp.3~ (2015)
19. Kim JW, "Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study", Br J Oral Maxillofac Surg (2014)
20. Blick SK, "Teriparatide: a review of its use in osteoporosis", Drugs, 68, pp.2709~ (2008)
21. Rubin MR, "The anabolic effects of parathyroid hormone therapy", Clin Geriatr Med, 19, pp.415~ (2003)
22. Sim IW, "Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial", J Clin Oncol, 38, pp.2971~ (2020)

관련 논문AI추천